FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

	Check this box if no longer subject to							
)	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MUELLER PETER						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								heck	all applic	cable)	g Pers	son(s) to Iss 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET					07/	3. Date of Earliest Transaction (Month/Day/Year) 07/15/2009 4. If Amendment, Date of Original Filed (Month/Day/Year)									X Office (give title below) below) EVP Global R&D, CSO 6. Individual or Joint/Group Filing (Check Applicable					
(Street) CAMBRIDGE MA 02139					- -									Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																				
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed o	f, or B	eneficia	lly (Owned	l				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execution		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Securit Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price			ction(s) 3 and 4)			(Instr. 4)	
Common Stock 07/15/200					2009)9			M		2,400	A	\$9.69		119	9,274		D		
Common Stock 07/15/200					2009)9		S ⁽¹⁾		2,400	D	\$32.88(2	2)(3)	116,874			D			
Common Stock															3,882			I .	401(k)	
		Т	able I								posed of, converti			y O	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transa Code (8)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owr Forr Dire or Ir (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares							
Stock Ontion	\$9.69	07/15/2009			M			2,400	(4)		03/16/2014	Commor	2,400		\$0	\$0 0		D		

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Mueller's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$32.88 (range \$32.50 to \$33.09).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

** Signature of Reporting Person

In-Fact

07/16/2009

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.